Prestige Consumer HealthcarePBH.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, Prestige Consumer Healthcare (PBH.N) trades at a P/E of 13.70x, P/B of 1.24x, P/S of 2.14x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 33rd percentile over the trailing 10Y window (vs. 15th percentile over 3Y); P/B sits at the 5th percentile over the trailing 10Y window (vs. 8th percentile over 3Y); P/S sits at the 32nd percentile over the trailing 10Y window (vs. 10th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 21st percentile within its industry and the 34th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.18%, ranking at the 90th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 27.9 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Prestige Consumer Healthcare operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: PBH · PBH
Want the full picture on whether Prestige Consumer Healthcare (PBH.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 13.70 | ||||||
| P/B (MRQ) | 1.24 | ||||||
| P/S (TTM) | 2.14 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 2.18% |